MCID: PCK003
MIFTS: 65

Pick Disease of Brain

Categories: Genetic diseases, Rare diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Pick Disease of Brain

MalaCards integrated aliases for Pick Disease of Brain:

Name: Pick Disease of Brain 57 12
Pick's Disease 12 53 54 29 6 15
Pick Disease of the Brain 53 75 44 73
Pick Disease 57 12 76 13
Dementia with Lobar Atrophy and Neuronal Cytoplasmic Inclusions 57 53 75
Lobar Atrophy of Brain 57 12 75
Dementia in Pick's Disease 12
Lobar Atrophy of the Brain 53
Pick's Disease of Brain 40
Picks Disease 55
Pidb 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant
isolated cases

Miscellaneous:
phenotypic overlap with frontotemporal dementia


HPO:

32
pick disease of brain:
Inheritance autosomal dominant inheritance sporadic


Classifications:



Summaries for Pick Disease of Brain

NINDS : 54 Frontotemporal dementia (FTD) describes a clinical syndrome associated with shrinking of the frontal and temporal anterior lobes of the brain. Originally known as Pick’s disease, the name and classification of FTD has been a topic of discussion for over a century.  The current designation of the syndrome groups together Pick’s disease, primary progressive aphasia, and semantic dementia as FTD.  Some doctors propose adding corticobasal degeneration and progressive supranuclear palsy to FTD and calling the group Pick Complex.  These designations will continue to be debated.  As it is defined today, the symptoms of FTD fall into two clinical patterns that involve either (1) changes in behavior, or (2) problems with language.  The first type features behavior that can be either impulsive (disinhibited) or bored and listless (apathetic) and includes inappropriate social behavior; lack of social tact; lack of empathy; distractability; loss of insight into the behaviors of oneself and others; an increased interest in sex; changes in food preferences; agitation or, conversely, blunted emotions; neglect of personal hygiene; repetitive or compulsive behavior, and decreased energy and motivation.  The second type primarily features symptoms of language disturbance, including difficulty making or understanding speech, often in conjunction with the behavioral type’s symptoms.  Spatial skills and memory remain intact.  There is a strong genetic component to the disease; FTD often runs in families.

MalaCards based summary : Pick Disease of Brain, also known as pick's disease, is related to niemann-pick disease, type c1 and kluver-bucy syndrome, and has symptoms including myoclonus and personality changes. An important gene associated with Pick Disease of Brain is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Neuroscience and p75(NTR)-mediated signaling. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and testes, and related phenotypes are hyperorality and stereotypy

OMIM : 57 Pick disease refers to the neuropathologic finding of 'Pick bodies,' which are argyrophilic, intraneuronal inclusions, and 'Pick cells,' which are enlarged neurons. The clinical correlates of Pick disease of brain include those of frontotemporal dementia, which encompass the behavioral variant of FTD, semantic dementia, and progressive nonfluent aphasia (summary by Piguet et al., 2011). Kertesz (2003) suggested the term 'Pick complex' to represent the overlapping syndromes of FTD, primary progressive aphasia (PPA), corticobasal degeneration (CBD), progressive supranuclear palsy (601104), and FTD with motor neuron disease. He noted that frontotemporal dementia may also be referred to as 'clinical Pick disease,' and that the term 'Pick disease' should be restricted to the pathologic finding of Pick bodies. (172700)

UniProtKB/Swiss-Prot : 75 Pick disease of the brain: A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.

NIH Rare Diseases : 53 Pick’s disease is a neurological condition characterized by a slowly progressive deterioration of behavior, personality, or language. People with Pick's disease have abnormal substances (called Pick bodies) inside nerve cells in the damaged areas of the brain. Pick bodies contain an abnormal form of a protein called tau. This protein is found in all nerve cells, but people with Pick's disease have an abnormal amount or type of this protein. Symptoms often present sometime in the 50s, though it can occur as early as age 20 or as late as age 80. The course of the disease varies from person to person. The underlying cause of Pick's disease is unknown. In some cases, the disease runs in families. While there is no treatment to slow the progression of the disease, medications can be used to treat individual symptoms.

Wikipedia : 76 Pick\'s disease is a term that can be used in two different ways. It has traditionally been used as a... more...

Related Diseases for Pick Disease of Brain

Diseases related to Pick Disease of Brain via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
# Related Disease Score Top Affiliating Genes
1 niemann-pick disease, type c1 34.7 APP MAPT SNCA
2 kluver-bucy syndrome 30.1 APP MAPT PSEN1
3 multiple system atrophy 1 30.1 MAPT SNCA SQSTM1
4 tremor 29.9 FUS MAPT SNCA
5 corticobasal degeneration 29.7 CRYAB MAPT RPS27A TARDBP
6 amyloidosis 29.5 APOE APP PSEN1 SNCA
7 supranuclear palsy, progressive, 1 28.9 APOE APP CHAT GRN MAPT PSEN1
8 frontotemporal dementia 26.8 APOE APP CRYAB FUS GRN MAPT
9 alzheimer disease 26.0 APOE APP CHAT CLU GRN MAPT
10 dementia 25.8 APOE APP CHAT FUS GRN MAPT
11 niemann-pick disease, type a 12.6
12 niemann-pick disease, type b 12.6
13 niemann-pick disease 12.6
14 niemann-pick disease, type c2 12.5
15 niemann-pick disease type c, juvenile neurologic onset 12.0
16 niemann-pick disease type c, severe perinatal form 11.9
17 niemann-pick disease type c, late infantile neurologic onset 11.9
18 niemann-pick disease type c, severe early infantile neurologic onset 11.9
19 niemann-pick disease type c, adult neurologic onset 11.9
20 acid sphingomyelinase deficiency 11.4
21 sea-blue histiocyte disease 11.2
22 sphingolipidosis 11.1
23 simultanagnosia 10.7 APOE MAPT
24 parkinson disease 3, autosomal dominant 10.7 MAPT SNCA
25 posterior cortical atrophy 10.7 APOE MAPT
26 alzheimer disease 4 10.7 APOE PSEN1
27 early-onset, autosomal dominant alzheimer disease 10.7 APP PSEN1
28 postencephalitic parkinson disease 10.6 MAPT SNCA TARDBP
29 neuronal intranuclear inclusion disease 10.5 MAPT RPS27A SNCA
30 alexia 10.5 APOE PSEN1 TARDBP
31 head injury 10.5 APOE CHAT
32 synucleinopathy 10.4 APP MAPT SNCA
33 amyotrophic lateral sclerosis type 6 10.4 FUS TARDBP
34 lipoprotein glomerulopathy 10.4 APOE CLU
35 rem sleep behavior disorder 10.4 RPS27A SNCA
36 amyotrophic lateral sclerosis 18 10.4 FUS TARDBP
37 amyotrophic lateral sclerosis type 14 10.3 FUS TARDBP
38 marcus gunn phenomenon 10.3 CHAT TUBB3
39 senile plaque formation 10.3 APOE APP CHAT
40 expressive language disorder 10.2 FUS PSEN1 TARDBP
41 olfactory nerve neoplasm 10.2 CHGA TUBB3
42 lethal congenital contracture syndrome 1 10.2 FUS TARDBP
43 urethral benign neoplasm 10.2 APP CHGA
44 familial idiopathic basal ganglia calcification 10.2 APOE APP MAPT PSEN1
45 alzheimer disease 2 10.2 APOE APP MAPT PSEN1
46 cerebral amyloid angiopathy, cst3-related 10.2 APOE APP MAPT PSEN1
47 neuronitis 10.2
48 pineocytoma 10.2 CHGA TUBB3
49 prosopagnosia 10.1 GRN PSEN1
50 myopathy, myofibrillar, 1 10.1 CRYAB RPS27A

Graphical network of the top 20 diseases related to Pick Disease of Brain:



Diseases related to Pick Disease of Brain

Symptoms & Phenotypes for Pick Disease of Brain

Symptoms via clinical synopsis from OMIM:

57
Neurologic Behavioral Psychiatric Manifestations:
irritability
disinhibition
apathy
personality changes
echolalia
more
Neurologic Central Nervous System:
language impairment
frontotemporal dementia
neuronal loss
frontotemporal lobar atrophy with 'knife-edge' distinction
atrophy may be more severe in the left hemisphere
more

Clinical features from OMIM:

172700

Human phenotypes related to Pick Disease of Brain:

32 (show all 16)
# Description HPO Frequency HPO Source Accession
1 hyperorality 32 HP:0000710
2 stereotypy 32 HP:0000733
3 disinhibition 32 HP:0000734
4 irritability 32 HP:0000737
5 apathy 32 HP:0000741
6 inappropriate laughter 32 HP:0000748
7 personality changes 32 HP:0000751
8 frontotemporal dementia 32 HP:0002145
9 gliosis 32 HP:0002171
10 language impairment 32 HP:0002463
11 primitive reflex 32 HP:0002476
12 neuronal loss in central nervous system 32 HP:0002529
13 polyphagia 32 HP:0002591
14 echolalia 32 HP:0010529
15 emotional blunting 32 HP:0030213
16 perseveration 32 HP:0030223

UMLS symptoms related to Pick Disease of Brain:


myoclonus, personality changes

MGI Mouse Phenotypes related to Pick Disease of Brain:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 CHAT APOE CLU APP CRYAB GRN
2 homeostasis/metabolism MP:0005376 10.21 CD59 GRN CHAT APOE CHGA CLU
3 cellular MP:0005384 10.2 GRN APOE APP CRYAB CD59 SNCA
4 mortality/aging MP:0010768 10.15 CD59 GRN CHAT APOE CHGA APP
5 cardiovascular system MP:0005385 10.08 CHAT CHGA APOE CLU APP SNCA
6 immune system MP:0005387 10.06 APOE CLU APP GRN SNCA SQSTM1
7 nervous system MP:0003631 10 GRN CHAT APOE CLU APP SNCA
8 muscle MP:0005369 9.92 CHAT APOE CLU APP CRYAB MAPT
9 no phenotypic analysis MP:0003012 9.7 GRN APOE CHGA APP SNCA MAPT
10 renal/urinary system MP:0005367 9.5 CD59 APOE CHGA CLU SNCA MAPT
11 reproductive system MP:0005389 9.23 CD59 GRN CHAT APOE CHGA APP

Drugs & Therapeutics for Pick Disease of Brain

Drugs for Pick Disease of Brain (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
3
Citalopram Approved Phase 4 59729-33-8 2771
4
Iodine Approved, Investigational Phase 4 7553-56-2 807
5
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
6 Antiparkinson Agents Phase 4,Phase 3,Phase 2
7 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
9 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1,Not Applicable
10 Radiopharmaceuticals Phase 4,Phase 2,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
12 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
13 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
14 Antidepressive Agents Phase 4,Phase 2,Phase 1
15 Antidepressive Agents, Second-Generation Phase 4
16 Neurotransmitter Uptake Inhibitors Phase 4
17 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
18 Serotonin Agents Phase 4,Phase 3
19 Serotonin Uptake Inhibitors Phase 4
20 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Anti-Inflammatory Agents Phase 4,Phase 1
23 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
24 Analgesics Phase 4,Phase 1
25 Analgesics, Non-Narcotic Phase 4,Phase 1
26 cadexomer iodine Phase 4
27
Serotonin Investigational, Nutraceutical Phase 4,Phase 3 50-67-9 5202
28 Calamus Nutraceutical Phase 4
29
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
30
Methylene blue Approved, Investigational Phase 3 61-73-4
31
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
32
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
33
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
34
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
36
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
37
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
38
Iron Approved Phase 2, Phase 3 7439-89-6 23925
39 tannic acid Approved, Nutraceutical Phase 3
40
1-Deoxynojirimycin Experimental Phase 3,Phase 2 19130-96-2 1374
41 Anti-HIV Agents Phase 3,Phase 2,Phase 1
42 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1
43 Cardiac Glycosides Phase 3,Phase 2,Phase 1
44 Glycoside Hydrolase Inhibitors Phase 3,Phase 2,Phase 1
45 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
46 Alkylating Agents Phase 2, Phase 3
47 Antilymphocyte Serum Phase 2, Phase 3
48 Antineoplastic Agents, Alkylating Phase 2, Phase 3
49 Antirheumatic Agents Phase 2, Phase 3,Phase 1
50 Immunosuppressive Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 160)
# Name Status NCT ID Phase Drugs
1 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
2 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
3 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
4 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
5 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
6 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
7 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
8 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
9 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
10 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
11 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
12 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
13 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
14 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
15 SurVival of Lysosomal Acid Lipase Deficiency (LAL-D) Infants Treated With SebelipAse aLfa Active, not recruiting NCT01371825 Phase 2, Phase 3 Sebelipase alfa (SBC-102)
16 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Not yet recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet
17 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
18 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
19 Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102 Terminated NCT01473875 Phase 2, Phase 3 SBC-102
20 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
21 Effects of Tolcapone on Frontotemporal Dementia Unknown status NCT00604591 Phase 2 Tolcapone;Placebo
22 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
23 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
24 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
25 Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
26 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
27 Double Blind Trial of DC Polarization in FTD Completed NCT00117858 Phase 2
28 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Completed NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray
29 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
30 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
31 Intranasal Oxytocin for Frontotemporal Dementia Recruiting NCT03260920 Phase 2 Syntocinon
32 Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia Recruiting NCT02862210 Phase 2 Lithium Carbonate;Placebo
33 Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Recruiting NCT03471143 Phase 1, Phase 2 2-Hydroxypropyl-Beta-Cyclodextrin
34 Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Recruiting NCT01937013 Phase 2 Intranasal oxytocin;Saline Nasal Mist
35 Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
36 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
37 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
38 F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis Active, not recruiting NCT02414230 Phase 2 Drug: F 18 T807
39 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
40 Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency Active, not recruiting NCT02193867 Phase 2 sebelipase alfa
41 F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E) Enrolling by invitation NCT02414282 Phase 2 F 18 T807
42 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Enrolling by invitation NCT02676843 Phase 2 18F-AV-1451
43 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
44 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
45 F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) Withdrawn NCT02707978 Phase 2 F 18 T807
46 Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia Unknown status NCT00674960 Phase 1
47 Far Infrared Radiation Treatment of Dementia and Other Mental Illness Unknown status NCT00574054 Phase 1
48 Safety Study of Intranasal Oxytocin in Frontotemporal Dementia Completed NCT01386333 Phase 1 oxytocin;Saline Nasal Mist
49 Direct Current Brain Polarization in Frontotemporal Dementia Completed NCT00077896 Phase 1
50 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270

Search NIH Clinical Center for Pick Disease of Brain

Cochrane evidence based reviews: pick disease of the brain

Genetic Tests for Pick Disease of Brain

Genetic tests related to Pick Disease of Brain:

# Genetic test Affiliating Genes
1 Pick's Disease 29 MAPT PSEN1

Anatomical Context for Pick Disease of Brain

MalaCards organs/tissues related to Pick Disease of Brain:

41
Brain, Temporal Lobe, Testes, Liver, Cortex, Prefrontal Cortex, Bone

Publications for Pick Disease of Brain

Articles related to Pick Disease of Brain:

(show top 50) (show all 283)
# Title Authors Year
1
Pick's disease with neuronal four-repeat tau accumulation in the basal ganglia, brain stem nuclei and cerebellum. ( 28691164 )
2017
2
A Novel Triple Repeat Mutant Tau Transgenic Model That Mimics Aspects of Pick's Disease and Fronto-Temporal Tauopathies. ( 25803611 )
2015
3
An autopsy case of incipient Pick's disease: immunohistochemical profile of early-stage Pick body formation. ( 24444359 )
2014
4
Primary progressive apraxia of speech (AOS) in a patient with Pick's disease with Pick bodies: a neuropsychological and anatomical study and review of literatures. ( 22500674 )
2013
5
Immunolocalization of an Amino-Terminal Fragment of Apolipoprotein E in the Pick's Disease Brain. ( 24312462 )
2013
6
'Limits and current knowledge of Pick's disease: its differential diagnosis'. A translation of the 1957 Delay, Brion, Escourolle article. ( 22554132 )
2013
7
Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. ( 22713404 )
2013
8
C1q, the classical complement pathway protein binds Hirano bodies in Pick's disease. ( 23512330 )
2013
9
Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. ( 22558197 )
2012
10
Pick's disease. ( 22411252 )
2012
11
Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease. ( 21881831 )
2011
12
Neuronal and glial tau pathology in early frontotemporal lobar degeneration-tau, Pick's disease subtype. ( 20022024 )
2010
13
The journey through Pick's Disease with a loved one: a personal account. ( 20487487 )
2010
14
Frontotemporal dementia, Pick's disease. ( 20420119 )
2010
15
Clinicopathological characterization of Pick's disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions. ( 19194716 )
2009
16
Caspase-cleaved TAR DNA-binding protein-43 in Pick's disease. ( 20411029 )
2009
17
Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. ( 19693433 )
2009
18
Up-regulation of adenosine A1 receptors in frontal cortex from Pick's disease cases. ( 18052973 )
2007
19
Pick's disease with Pick bodies: an unusual autopsy case showing degeneration of the pontine nucleus, dentate nucleus, Clarke's column, and lower motor neuron. ( 17319287 )
2007
20
Expression of transcription factors c-Fos, c-Jun, CREB-1 and ATF-2, and caspase-3 in relation with abnormal tau deposits in Pick's disease. ( 16496165 )
2006
21
Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick's disease. ( 16987245 )
2006
22
The corpus callosum in Pick's disease, Alzheimer's disease, and amyotrophic lateral sclerosis: gliosis implies possible clinical consequence. ( 16526588 )
2006
23
Pick's disease. ( 17076146 )
2006
24
An individualized approach to treatment for alzheimer's disease, pick's disease, and other dementias. ( 17062555 )
2006
25
Pathological heterogeneity of the precentral gyrus in Pick's disease: a study of 16 autopsy cases. ( 16609852 )
2006
26
Adenosine A2A receptors are up-regulated in Pick's disease frontal cortex. ( 17107593 )
2006
27
Pick's disease with Pick bodies combined with progressive supranuclear palsy without tuft-shaped astrocytes: a clinical, neuroradiologic and pathological study of an autopsied case. ( 16771179 )
2006
28
Progress in clinical neurosciences: Frontotemporal dementia-pick's disease. ( 16736722 )
2006
29
Notch-1 immunoexpression is increased in Alzheimer's and Pick's disease. ( 16473372 )
2006
30
Abnormal alpha-synuclein solubility, aggregation and nitration in the frontal cortex in Pick's disease. ( 16516382 )
2006
31
BetaII-tubulin and phospho-tau aggregates in Alzheimer's disease and Pick's disease. ( 16006664 )
2005
32
Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer's and Pick's disease. ( 15661359 )
2005
33
Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. ( 16014652 )
2005
34
Presenile dementia mimicking Pick's disease: an autopsy case of localized amygdala degeneration with character change and emotional disorder. ( 16193841 )
2005
35
Ubiquitin and ubiquitin-related proteins in the brains of patients with atypical Pick's disease without Pick bodies and dementia with motor neuron disease. ( 15641590 )
2004
36
Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. ( 14991385 )
2004
37
Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease. ( 14689204 )
2004
38
Pick's disease pathology of a missense mutation of S305N of frontotemporal dementia and parkinsonism linked to chromosome 17: another phenotype of S305N. ( 15178939 )
2004
39
Frontotemporal dementia/Pick's disease. ( 15210543 )
2004
40
Genetic aspects of Alzheimer's disease, Pick's disease, and other dementias. ( 15359559 )
2004
41
Synaptophysin immunoreactivity in Pick's disease: comparison with Alzheimer's disease and dementia with Lewy bodies. ( 15633942 )
2004
42
A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. ( 15122701 )
2004
43
Ubiquitin and ubiquitin-related proteins in neurons and dendrites of brains of atypical Pick's disease without Pick bodies. ( 15068171 )
2004
44
Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. ( 12615642 )
2003
45
Alterations of muscarinic acetylcholine receptors in atypical Pick's disease without Pick bodies. ( 12810794 )
2003
46
Pick's disease. ( 12531941 )
2003
47
An N-terminal fragment of ProSAAS (a granin-like neuroendocrine peptide precursor) is associated with tau inclusions in Pick's disease. ( 12914799 )
2003
48
Clinicopathological study of two subtypes of Pick's disease in Japan. ( 12457075 )
2003
49
Epidemiology and genetics of frontotemporal dementia/Pick's disease. ( 12833366 )
2003
50
Another phenotype of frontotemporal dementia and parkinsonism linked to chromosome-17 (FTDP-17) with a missense mutation of S305N closely resembling Pick's disease. ( 12928922 )
2003

Variations for Pick Disease of Brain

UniProtKB/Swiss-Prot genetic disease variations for Pick Disease of Brain:

75
# Symbol AA change Variation ID SNP ID
1 MAPT p.Lys574Thr VAR_010344 rs63750129
2 MAPT p.Gly706Arg VAR_010352 rs63750512
3 MAPT p.Ser637Phe VAR_019665 rs63750635
4 MAPT p.Lys686Ile VAR_019668 rs63751264

ClinVar genetic disease variations for Pick Disease of Brain:

6
(show all 32)
# Gene Variation Type Significance SNP ID Assembly Location
1 MAPT NM_005910.5(MAPT): c.1165G> A (p.Gly389Arg) single nucleotide variant Likely pathogenic rs63750512 GRCh37 Chromosome 17, 44101376: 44101376
2 MAPT NM_005910.5(MAPT): c.1165G> A (p.Gly389Arg) single nucleotide variant Likely pathogenic rs63750512 GRCh38 Chromosome 17, 46024010: 46024010
3 MAPT NM_016835.4(MAPT): c.1721A> C (p.Lys574Thr) single nucleotide variant Pathogenic rs63750129 GRCh37 Chromosome 17, 44073978: 44073978
4 MAPT NM_016835.4(MAPT): c.1721A> C (p.Lys574Thr) single nucleotide variant Pathogenic rs63750129 GRCh38 Chromosome 17, 45996612: 45996612
5 MAPT NM_016835.4(MAPT): c.2057A> T (p.Lys686Ile) single nucleotide variant Pathogenic rs63751264 GRCh37 Chromosome 17, 44096092: 44096092
6 MAPT NM_016835.4(MAPT): c.2057A> T (p.Lys686Ile) single nucleotide variant Pathogenic rs63751264 GRCh38 Chromosome 17, 46018726: 46018726
7 MAPT NM_016835.4(MAPT): c.1910C> T (p.Ser637Phe) single nucleotide variant Pathogenic rs63750635 GRCh37 Chromosome 17, 44091652: 44091652
8 MAPT NM_016835.4(MAPT): c.1910C> T (p.Ser637Phe) single nucleotide variant Pathogenic rs63750635 GRCh38 Chromosome 17, 46014286: 46014286
9 PSEN1 NM_000021.3(PSEN1): c.488A> G (p.His163Arg) single nucleotide variant Pathogenic rs63750590 GRCh37 Chromosome 14, 73653568: 73653568
10 PSEN1 NM_000021.3(PSEN1): c.488A> G (p.His163Arg) single nucleotide variant Pathogenic rs63750590 GRCh38 Chromosome 14, 73186860: 73186860
11 PSEN1 NM_000021.3(PSEN1): c.737C> A (p.Ala246Glu) single nucleotide variant Pathogenic rs63750526 GRCh37 Chromosome 14, 73659540: 73659540
12 PSEN1 NM_000021.3(PSEN1): c.737C> A (p.Ala246Glu) single nucleotide variant Pathogenic rs63750526 GRCh38 Chromosome 14, 73192832: 73192832
13 PSEN1 NM_000021.3(PSEN1): c.1229G> A (p.Cys410Tyr) single nucleotide variant Pathogenic rs661 GRCh37 Chromosome 14, 73683933: 73683933
14 PSEN1 NM_000021.3(PSEN1): c.1229G> A (p.Cys410Tyr) single nucleotide variant Pathogenic rs661 GRCh38 Chromosome 14, 73217225: 73217225
15 PSEN1 NM_000021.3(PSEN1): c.617G> C (p.Gly206Ala) single nucleotide variant Pathogenic rs63750082 GRCh37 Chromosome 14, 73659420: 73659420
16 PSEN1 NM_000021.3(PSEN1): c.617G> C (p.Gly206Ala) single nucleotide variant Pathogenic rs63750082 GRCh38 Chromosome 14, 73192712: 73192712
17 PSEN1 NM_000021.3(PSEN1): c.548G> T (p.Gly183Val) single nucleotide variant Pathogenic rs63751068 GRCh37 Chromosome 14, 73653628: 73653628
18 PSEN1 NM_000021.3(PSEN1): c.548G> T (p.Gly183Val) single nucleotide variant Pathogenic rs63751068 GRCh38 Chromosome 14, 73186920: 73186920
19 PSEN1 NM_000021.3(PSEN1): c.1292C> A (p.Ala431Glu) single nucleotide variant Pathogenic rs63750083 GRCh37 Chromosome 14, 73685885: 73685885
20 PSEN1 NM_000021.3(PSEN1): c.1292C> A (p.Ala431Glu) single nucleotide variant Pathogenic rs63750083 GRCh38 Chromosome 14, 73219177: 73219177
21 PSEN1 NM_000021.3(PSEN1): c.236C> T (p.Ala79Val) single nucleotide variant Pathogenic rs63749824 GRCh37 Chromosome 14, 73637653: 73637653
22 PSEN1 NM_000021.3(PSEN1): c.236C> T (p.Ala79Val) single nucleotide variant Pathogenic rs63749824 GRCh38 Chromosome 14, 73170945: 73170945
23 PSEN1 NM_000021.3(PSEN1): c.344A> G (p.Tyr115Cys) single nucleotide variant Pathogenic rs63750450 GRCh37 Chromosome 14, 73640279: 73640279
24 PSEN1 NM_000021.3(PSEN1): c.344A> G (p.Tyr115Cys) single nucleotide variant Pathogenic rs63750450 GRCh38 Chromosome 14, 73173571: 73173571
25 PSEN1 NM_000021.3(PSEN1): c.626G> T (p.Gly209Val) single nucleotide variant Pathogenic rs63750053 GRCh37 Chromosome 14, 73659429: 73659429
26 PSEN1 NM_000021.3(PSEN1): c.626G> T (p.Gly209Val) single nucleotide variant Pathogenic rs63750053 GRCh38 Chromosome 14, 73192721: 73192721
27 MAPT NM_001123066.3(MAPT): c.623delG (p.Gly208Alafs) deletion Uncertain significance rs1085307079 GRCh38 Chromosome 17, 45983427: 45983427
28 MAPT NM_001123066.3(MAPT): c.623delG (p.Gly208Alafs) deletion Uncertain significance rs1085307079 GRCh37 Chromosome 17, 44060793: 44060793
29 PSEN1 NM_000021.3(PSEN1): c.-296C> T single nucleotide variant Benign/Likely benign rs1800839 GRCh38 Chromosome 14, 73136423: 73136423
30 PSEN1 NM_000021.3(PSEN1): c.-296C> T single nucleotide variant Benign/Likely benign rs1800839 GRCh37 Chromosome 14, 73603131: 73603131
31 PSEN1 NM_000021.3(PSEN1): c.-528C> G single nucleotide variant Benign rs34086577 GRCh37 Chromosome 14, 73602899: 73602899
32 PSEN1 NM_000021.3(PSEN1): c.-528C> G single nucleotide variant Benign rs34086577 GRCh38 Chromosome 14, 73136191: 73136191

Expression for Pick Disease of Brain

Search GEO for disease gene expression data for Pick Disease of Brain.

Pathways for Pick Disease of Brain

GO Terms for Pick Disease of Brain

Cellular components related to Pick Disease of Brain according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.97 APP CHGA CLU PSEN1 SQSTM1
2 cell surface GO:0009986 9.95 APP CD59 CLU CRYAB PSEN1
3 dendrite GO:0030425 9.85 APOE FUS MAPT PSEN1 TUBB3
4 perinuclear region of cytoplasm GO:0048471 9.85 APP CHGA CLU FUS PSEN1 SNCA
5 rough endoplasmic reticulum GO:0005791 9.69 APP PSEN1 SNCA
6 dendritic spine GO:0043197 9.62 APP CRYAB FUS MAPT
7 nuclear outer membrane GO:0005640 9.61 PSEN1 SNCA
8 inclusion body GO:0016234 9.59 SNCA SQSTM1
9 amyloid-beta complex GO:0106003 9.56 APOE CLU
10 growth cone GO:0030426 9.56 APP MAPT PSEN1 SNCA
11 ciliary rootlet GO:0035253 9.54 APP PSEN1
12 main axon GO:0044304 9.48 APP MAPT
13 neuronal cell body GO:0043025 9.43 APOE FUS MAPT PSEN1 SNCA TUBB3
14 neurofibrillary tangle GO:0097418 9.4 CLU MAPT
15 chromaffin granule GO:0042583 9.16 CHGA CLU
16 axon GO:0030424 9.1 APP CRYAB MAPT PSEN1 SNCA TUBB3
17 nucleus GO:0005634 10.36 APOE CHAT CLU CRYAB FUS MAPT
18 cytoplasm GO:0005737 10.31 APOE APP CHAT CLU CRYAB FUS
19 extracellular exosome GO:0070062 10.18 APOE APP CD59 CLU CRYAB GRN
20 extracellular region GO:0005576 10.17 APOE APP CD59 CHGA CLU GRN
21 Golgi apparatus GO:0005794 10.08 APOE APP CLU CRYAB PSEN1 SNCA
22 extracellular space GO:0005615 10.03 APOE APP CD59 CHGA CLU GRN

Biological processes related to Pick Disease of Brain according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.96 PSEN1 RPS27A SNCA SQSTM1
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 APP CLU RPS27A
3 negative regulation of neuron apoptotic process GO:0043524 9.86 APOE PSEN1 SNCA
4 response to oxidative stress GO:0006979 9.84 APOE APP PSEN1
5 Notch signaling pathway GO:0007219 9.82 APP PSEN1 RPS27A
6 negative regulation of gene expression GO:0010629 9.77 APOE APP CRYAB MAPT TARDBP
7 negative regulation of protein phosphorylation GO:0001933 9.76 PSEN1 SNCA TARDBP
8 negative regulation of neuron death GO:1901215 9.72 APOE CHGA SNCA
9 cellular protein metabolic process GO:0044267 9.72 APOE APP PSEN1 RPS27A SNCA
10 positive regulation of dendritic spine development GO:0060999 9.69 APOE PSEN1
11 positive regulation of endocytosis GO:0045807 9.69 APOE SNCA
12 regulation of long-term neuronal synaptic plasticity GO:0048169 9.68 APP SNCA
13 regulation of protein binding GO:0043393 9.68 APP PSEN1
14 response to lead ion GO:0010288 9.67 APP MAPT
15 regulation of neuronal synaptic plasticity GO:0048168 9.67 APOE SNCA
16 regulation of neuron death GO:1901214 9.67 CLU SNCA
17 reverse cholesterol transport GO:0043691 9.65 APOE CLU
18 positive regulation of long-term synaptic potentiation GO:1900273 9.65 APP SQSTM1
19 positive regulation of receptor recycling GO:0001921 9.64 PSEN1 SNCA
20 supramolecular fiber organization GO:0097435 9.63 MAPT SNCA
21 amyloid precursor protein metabolic process GO:0042982 9.63 APOE PSEN1
22 positive regulation of neuron death GO:1901216 9.63 CLU MAPT SNCA
23 virion assembly GO:0019068 9.62 APOE RPS27A
24 positive regulation of amyloid-beta formation GO:1902004 9.61 APP CLU
25 negative regulation of protein homooligomerization GO:0032463 9.61 CLU CRYAB
26 amyloid fibril formation GO:1990000 9.6 APP MAPT
27 negative regulation of amyloid-beta formation GO:1902430 9.59 APOE CLU
28 negative regulation of long-term synaptic potentiation GO:1900272 9.58 APOE APP
29 modulation of age-related behavioral decline GO:0090647 9.57 APP PSEN1
30 neuron projection maintenance GO:1990535 9.56 APP PSEN1
31 protein import GO:0017038 9.54 APOE CLU
32 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.52 APP PSEN1
33 negative regulation of amyloid fibril formation GO:1905907 9.51 CLU CRYAB
34 astrocyte activation involved in immune response GO:0002265 9.49 APP PSEN1
35 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.48 APP PSEN1
36 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.43 APP PSEN1
37 microglial cell activation GO:0001774 9.43 CLU MAPT SNCA
38 regulation of amyloid-beta clearance GO:1900221 9.4 APOE CLU
39 astrocyte activation GO:0048143 9.33 APP MAPT PSEN1
40 synapse organization GO:0050808 9.26 APP MAPT PSEN1 SNCA
41 positive regulation of amyloid fibril formation GO:1905908 8.92 APOE APP CLU PSEN1
42 apoptotic process GO:0006915 10.04 APP CLU PSEN1 SNCA SQSTM1
43 negative regulation of apoptotic process GO:0043066 10.02 CRYAB PSEN1 RPS27A SNCA SQSTM1

Molecular functions related to Pick Disease of Brain according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.62 APP MAPT SNCA SQSTM1
2 amyloid-beta binding GO:0001540 9.43 APOE CLU CRYAB
3 low-density lipoprotein particle receptor binding GO:0050750 9.37 APOE CLU
4 identical protein binding GO:0042802 9.23 APOE APP CRYAB FUS MAPT SNCA
5 lipoprotein particle binding GO:0071813 9.16 APOE MAPT
6 tau protein binding GO:0048156 9.13 APOE CLU SNCA

Sources for Pick Disease of Brain

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....